Showing results (141-150 of 162) with videos related to

Sort By:
Pageof 17
Developmental Cell|May 20, 2026
Human pancreatic progenitor organoids define genetic and epigenetic barriers to early PDAC transformationXian Zhang, Wilfred Wong, Hyein S Cho, et al.
Gynecologic and Obstetric Investigation|January 3, 2019
Ten-Year Comparison Study of Type 1 and 2 Endometrial Cancers: Risk Factors and OutcomesJacqueline Feinberg, Benjamin Albright, Jonathan Black, et al.
Molecular Cancer Therapeutics|September 4, 2015
Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In VivoSalvatore Lopez, Emiliano Cocco, Jonathan Black, et al.
Gynecologic Oncology|August 12, 2015
Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivoCarlton L Schwab, Diana P English, Jonathan Black, et al.
Cell Reports. Medicine|February 18, 2026
DeCAF defines clinical fibroblast subtypes and multidimensional tumor-stroma crosstalk shaping prognosis and immunotherapy responseXianlu Laura Peng, Ian C McCabe, Elena V Kharitonova, et al.
Journal of Cancer Research and Clinical Oncology|September 27, 2018
Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancerGary Altwerger, Esther B Florsheim, Gulden Menderes, et al.
Nature|June 22, 2018
Altered exocrine function can drive adipose wasting in early pancreatic cancerLaura V Danai, Ana Babic, Michael H Rosenthal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2017
SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu ExpressionGulden Menderes, Elena Bonazzoli, Stefania Bellone, et al.
Pageof 17